Evidence map›Paper›PMID 39386216›Full record

ArticleFrontiers in immunology2024

Selected stem cell populations in pediatric acute lymphoblastic leukemia.

Anna Krętowska-Grunwald, Małgorzata Sawicka-Żukowska, Aleksandra Starosz, Maryna Krawczuk-Rybak, Marcin Moniuszko, Kamil Grubczak

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna Krętowska-GrunwaldDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
Małgorzata Sawicka-ŻukowskaDepartment of Pediatric Oncology and Hematology, Medical University of Bialystok, Bialystok, Poland.
Aleksandra StaroszDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
Maryna Krawczuk-RybakDepartment of Pediatric Oncology and Hematology, Medical University of Bialystok, Bialystok, Poland.
Marcin MoniuszkoDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
Kamil GrubczakDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Acute lymphoblastic leukemia is characterized by a disturbed maturation of hematopoietic stem cells (HSCs) resulting in development of a malignant clone. Despite relatively positive outcome, there are still instances of disease relapse occurring due to ineffective disease eradication or primary leukemic clone alterations. Unclear significance of stem cells in the course of ALL led us to investigate and establish crucial changes in two stem cell populations - very small embryonic-like stem cells (VSELs) and HSCs during the induction phase of treatment. Methods: In a retrospective study selected stem cells in peripheral blood and bone marrow of 60 pediatric ALL subjects and 48 healthy controls were subjected to flow cytometric analysis at 4 different time points. Results: Both VSELs and HSCs were elevated at the moment of ALL diagnosis compared to healthy controls, but profoundly decline until day 15. Further observations revealed an increase in HSCs with a concomitant depletion of VSELs until week 12. ALL patients with high HSCs showed positive correlation with bone marrow blasts at diagnosis. Patients with lower VSELs or HSCs at diagnosis had slightly improved response to applied therapy. We observed higher initial bone marrow lymphoblast values in patients with lower VSELs or higher HSCs in the high-risk group. The significance of VSELs in predicting treatment outcome can be illustrated by lower day 15 MRD level of patients with lower VSELs at diagnosis. Discussion: We found HSCs and VSELs to be valid participants in pediatric ALL with possible contribution in the neoplastic process and prediction of initial treatment outcome.

Indexed as

Hematopoietic Stem CellsPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleFlow CytometryHumansInfantMaleNeoplasm, ResidualRetrospective Studiesacute lymphoblastic leukemiahematopoietic stem cellsregenerative medicinestromal cell-derived factor 1very small embryonic-like stem cells

Identifiers

PMID39386216
PMCPMC11461207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.